Trial Profile
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Registrational; Therapeutic Use
- Acronyms STAND
- Sponsors Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 24 Jan 2024 This trial has been Completed in Greece, According to European Clinical Trials Database record.
- 12 Dec 2023 Results of pooled analysis from studies (NCT0189536, NCT03264989, NCT03474965 and NCT03814746 )in patients with SCD, presented at 65th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2023 Results(n=252) presented at the 65th American Society of Hematology Annual Meeting and Exposition